Details of the Drug Combination

General Information of Drug Combination (ID: DC3IP0D)

Drug Combination Name
ABIRATERONE Topetecan
Indication
Disease Entry Status REF
Malignant melanoma Investigative [1]
Component Drugs ABIRATERONE   DM8V75C Topetecan   DMAE6LK
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: LOX IMVI
Zero Interaction Potency (ZIP) Score: 0.36
Bliss Independence Score: 7.73
Loewe Additivity Score: 4.36
LHighest Single Agent (HSA) Score: 10.66

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of ABIRATERONE
Disease Entry ICD 11 Status REF
Prostate cancer 2C82.0 Approved [2]
ABIRATERONE Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Steroid 17-alpha-monooxygenase (S17AH) TTRA5BZ CP17A_HUMAN Modulator [4]
------------------------------------------------------------------------------------
Indication(s) of Topetecan
Disease Entry ICD 11 Status REF
Small-cell lung cancer 2C25.Y Approved [3]
Topetecan Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
DNA topoisomerase I (TOP1) TTGTQHC TOP1_HUMAN Inhibitor [5]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Lung adenocarcinoma DCQEMCP MDA-MB-231 Investigative [1]
------------------------------------------------------------------------------------

References

1 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125976
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6745).
3 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 020671.
4 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
5 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).